ArticleDigital health
"Getting every smoker to participate and quit - GEMPAQ V2.0", a personalised smoking cessation smartphone app in Malaysia: A pilot randomised controlled trial.
Article in Digital health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite rigorous tobacco control efforts over many years, smoking prevalence in Malaysia remains high. This study evaluates the effectiveness of a novel smartphone smoking cessation app, tailored to users' five-factor personality traits, in increasing quit rates. Methods: A double-blind, parallel, two-arm randomised controlled pilot trial compared a personalised smoking cessation app (intervention) with a basic app (control). The online study, conducted across Malaysia with a 90-day follow-up, enrolled 152 adult smokers (N = 152). Results: Most participants were male (88.5%; mean age, 38.5 years [SD = 11.75]). In complete-case analysis (N = 87), the GEMPAQ V2.0 intervention group ( Conclusion: Personalised GEMPAQ V2.0 users appeared to demonstrate promising indicators of utilisation, including the number of apps assessed and usability over time, and reported encouraging quit rates, particularly among smokers with a dominant conscientiousness personality trait.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.